TRIM24: A Potential Breakthrough for Endocrine-Resistant Breast Cancer Treatment

Fast Summary:

• The latest edition of Proceedings of the National Academy of Sciences (Volume 122,Issue 33,August 2025) studies estrogen receptor alpha (ERα),a transcription factor central to breast cancer growth.
• ERα is the primary target for endocrine therapies in breast cancer treatment.
• Research highlights that resistance to these therapies remains a significant challenge.

Indian Opinion Analysis:
Breast cancer is one of the leading health concerns for Indian women, adn advancements in understanding mechanisms like ERα are critical globally and locally. Increased awareness about therapeutic resistance could push Indian researchers and policymakers toward prioritizing cutting-edge medical breakthroughs, better diagnoses, and affordable treatments in India’s healthcare system.As this issue impacts millions worldwide, its relevance drives global collaborations-including potential benefits for India through technology sharing or research partnerships.

Read More